GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE220097 4 V 1 ENZALUTAMIDE HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

SRC kinase signaling inhibitor 1

Gene

ARPIN-AP3S2 readthrough

Gene

zinc finger protein 883

Gene

CYP3A7-CYP3A51P readthrough

Gene

glucagon like peptide 1 receptor

Gene

PHD finger protein 12

Gene

transmembrane protein 98

Gene

protein kinase, membrane associated tyrosine/threonine 1

Gene

proline rich nuclear receptor coactivator 2

Gene

histidine triad nucleotide binding protein 3

  • Gene

    SRC kinase signaling inhibitor 1


  • Gene

    ARPIN-AP3S2 readthrough


  • Gene

    zinc finger protein 883


  • Gene

    CYP3A7-CYP3A51P readthrough


  • Gene

    glucagon like peptide 1 receptor


  • Gene

    PHD finger protein 12


  • Gene

    transmembrane protein 98


  • Gene

    protein kinase, membrane associated tyrosine/threonine 1


  • Gene

    proline rich nuclear receptor coactivator 2


  • Gene

    histidine triad nucleotide binding protein 3

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.